Cytochroma (Canada) clinical-stage specialty pharmaceutical company focused on products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease, closed a $45M Series C financing. Participants include Mitsubishi Tanabe Pharma Corporation, Vengrowth Advanced Life Sciences Fund, Caisse de Depot et Placement du Quebec, Novo, Canadian Medical Discoveries Fund, T2C2 Capital, GrowthWorks Canadian Fund, BDC Capital, and VentureLink Brighter Future Fund.